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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the beneﬁts and potential harms of shared decision-making for asthma.
B A C K G R O U N D
Description of the condition
Asthma is a chronic disease that affects the airways. It is usually
characterised by chronic inﬂammationof the airways, which causes
wheeze, shortness of breath, chest tightness, cough and variable
airﬂow limitation (GINA 2016). Symptoms vary signiﬁcantly in
their nature, frequency and severity both within and between in-
dividuals with a diagnosis of asthma. Day-to-day symptoms often
vary according to the presence of external stimuli (e.g. exercise,
allergens), and people with asthma can also experience ﬂare-ups
or ’exacerbations’ which are associated with signiﬁcant morbidity
and mortality worldwide (GINA 2016; Global Asthma Network
2014; NRAD 2014). The long-term goals of asthma manage-
ment are to maintain control of symptoms and to minimise the
risk of exacerbations, airﬂow limitation and treatment side-effects
(GINA 2016). Educating people to self-manage their asthma is
widely recognised as integral to achieving these goals both for
adults (Gibson 2002) and children (Guevara 2003).
Description of the intervention
Shared decision-making (SDM) should involve at least two partic-
ipants (the physician and the patient) and involve themutual shar-
ing of information to build a consensus about the preferred treat-
ment, which culminates in an agreed action (Charles 1997). Deci-
sions about the management of long-term conditions are based on
a multitude of factors, including the relative efﬁcacy and safety of
treatments, cost and palatability. SDM is a way of balancing these
factors by considering the values and preferences of the patient
and the opinions of the healthcare provider. Légaré 2013 describe
the three essential elements of SDM as follows.
1. Recognizing and acknowledging that a decision is required.
2. Knowing and understanding the best available evidence.
3. Incorporating the patient’s values and preferences into any
decision.
For asthma,management guidelines increasingly recognise the role
of “the patient and healthcare provider partnership” for a shared-
care approach (GINA 2016). Interventions to encourage patient-
centered care in clinical consultations across a range of condi-
tions generally put the onus on the healthcare provider (Dwamena
2012), but some are aimed at providing a pathway for patients
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or parents to better engage in their asthma care (e.g. Fiks 2015;
Wilson 2010), or amixture of both, and these different approaches
may have different aims and outcomes. Interventions aimed at
changing health provider behaviour might include open commu-
nications, identifying and addressing patient and family concerns
about asthma and its treatment, discussing treatment preferences
and barriers to implementation, shared development of treatment
goals, and encouraging active self-assessment and self-manage-
ment (NHLBI/NAEPP 2007).
How the intervention might work
The potential beneﬁt of SDM is dependent on the willingness
and ability of both sides to interact, which might depend on fac-
tors such as “ethnicity, literacy, understanding of health concepts
(health literacy), numeracy, beliefs about asthma andmedications,
desire for autonomy, and the health care system” (GINA 2016). As
such, SDMwill not necessarily be equally acceptable to all patients
or carers or applicable in the same way across healthcare contexts.
Beneﬁts of SDM may be seen for individuals and more widely
for health services and society by enhancing uptake of evidence-
based options and reducing overuse of options that have minimal
beneﬁts, thus reducing practice and geographic variations in care
and unnecessary expenditure (Coulter 2011; Légaré 2014).
Preferences for an active, collaborative or passive role in decision
making vary among populations, but patient roles are more of-
ten passive (Caress 2005; Sleath 2011), and many patients report
a desire to be more involved (Caress 2005). Patient preferences
for involvement in decision-making is related to education level,
perceptions of the healthcare provider, cost barriers of care and
psychosocial factors (Adams 2001), but preferences have not been
strongly associated with demography or asthma severity (Caress
2005). Nonetheless, there is a lack of evidence regarding how best
to achieve SDM in practice, especially in paediatric asthma with
regards to the child-parent relationship and adapting the emphasis
of SDM as the child matures (Rivera-Spoljaric 2014).
Organisational factors have been highlighted as a barrier to pa-
tients or families feeling satisﬁed with the role they played in
their asthma care, especially quality and duration of consultations
(Caress 2005), which will vary substantially across healthcare con-
texts. A narrative synthesis of the fast-growing ﬁeld of patient
involvement in medicine has identiﬁed the preparedness of ser-
vice systems as an enabler to successful SDM, alongside empow-
erment, patient education, communication for involvement, and
staff training (Snyder 2016). It is possible that engaging in SDM
may cause unintended harms, for example by allowing a patient
to choose an option without proper discussion of the harms and
beneﬁts, so it is important that staff are appropriately trained and
that decision aids are used correctly (Coulter 2011).
Why it is important to do this review
SDM may improve clinical outcomes and quality of life by edu-
cating and empowering patients to be actively involved in their
own health (Butz 2007; Wilson 2010). These interventions may
be particularly beneﬁcial in people with asthma as self-manage-
ment behaviours are important (Gibson 2002; Guevara 2003),
and make SDM particularly relevant to a population with asthma.
The US Institute of Medicine has prioritised SDM (Institute of
Medicine 2009), andAsthmaUK identiﬁedmethods to “empower
and enable people to take control of their own asthma” as a re-
search priority (Asthma UK 2011).
A recent Cochrane review found 43 studies that tested the effects
of interventions to encourage patient-centred care in clinical con-
sultations, and found mixed results in terms of patient satisfaction,
health behaviour and health status (Dwamena 2012). The authors
suggest complex interventions with condition-speciﬁc materials
aimed at both providers and patients might be promising, but ev-
idence was limited at this time. Similarly, Légaré 2014 focuses on
interventions aimed at improving uptake of SDM by healthcare
professionals with a primary focus on how well it is adopted in
practice. Reviewing evidence for SDM in asthma will allow us to
conduct wider searches in the asthma literature to ﬁnd additional
studies and to focus on important condition-speciﬁc outcomes.
The growth of SDM research means it is likely that new evidence
will have been published since the existing reviews.
O B J E C T I V E S
To assess the beneﬁts and potential harms of shared decision-mak-
ing for asthma.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs). We will in-
clude studies that use individual or cluster randomisation, but we
will exclude crossover studies due to the likelihood of carry-over
effects. We will exclude non-randomised studies because they will
restrict our ability to imply causation of intervention effects, and
are more likely to be subject to selection biases and confounders.
However, we will summarise narratively any non-randomised evi-
dence identiﬁed by the searches andwill contrast themwith our re-
sults in the discussion, particularly with regards to potential harms.
We will include studies reported as full-text articles, those pub-
lished as abstract only, and unpublished data.
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Types of participants
We will include studies of adults and children with a diagnosis of
asthma, either conﬁrmed by a physician or with spirometry ac-
cording to guidelines (e.g. GINA 2016). We will exclude stud-
ies that include participants with other long-term conditions, in
particular chronic obstructive pulmonary disease (COPD), un-
less separate results are presented for those with asthma. We will
also exclude studies looking at shared decision-making (SDM) in
asthma speciﬁcally for people with cognitive impairments, as the
interventions are likely to have a different focus. If a study includes
a subset of eligible participants (e.g. a mixed population that in-
cludes participants with other health conditions), we will only in-
clude it if we can analyse the disaggregated data for the eligible
participants separately.
Types of interventions
We will include studies that assess SDM interventions for people
with asthma. We will include interventions aimed at health pro-
fessionals (specialist, general practitioner, nurse, pharmacist etc.),
patients and their families or carers, or both. We will include stud-
ies that compare the intervention to usual care or a minimal con-
trol intervention separately from those comparing a SDM inter-
vention to another active intervention. We will exclude studies
of interventions that involve multiple components other than the
SDM intervention unless the control group also received them.
Types of outcome measures
Primary outcomes
1. Asthma-related quality of life (on a validated scale e.g.
Asthma Quality of Life Questionnaire (AQLQ)).
2. Patient/parent satisfaction.
3. Medication adherence.
Secondary outcomes
1. Exacerbations of asthma (leading to a course of oral
corticosteroids or unscheduled visit to a health professional).
2. Asthma control (e.g. Asthma Control Questionnaire
(ACQ)).
3. Acceptability/feasibility from the perspective of healthcare
professionals.
4. Adverse events (all).
Reporting one or more of the outcomes listed here in the study
will not be an inclusion criterion for the review.
We will prioritise any validated measures of patient/parent satis-
faction, medication adherence, asthma control and acceptability/
feasibility, but have not predeﬁned accepted measures in advance
so as not to restrict the analyses unnecessarily. If the study authors
use non-validated measures, or there is a mixture of validated and
non-validated measures across studies, we will assess which are suf-
ﬁciently similar for pooling to make sense.
We will extract and analyse data from both the parent and child
perspective in paediatric studies.
Search methods for identification of studies
Electronic searches
We will identify studies from the Cochrane Airways Group’s Spe-
cialised Register (CAGR), which is maintained by the Information
Specialist for the Cochrane Airways Group. The CAGR contains
trial reports identiﬁed through systematic searches of multiple bib-
liographic databases and handsearches of respiratory journals and
meeting abstracts (please see Appendix 1 for further details). We
will search all records in the CAGR using the search strategy in
Appendix 2. We have based our search terms for ’shared decision
making’ on those used in a Cochrane Review by Légaré 2014.
We will also conduct a search of ClinicalTrials.gov (http://
ClinicalTrials.gov) and the WHO International Clinical Trials
Registry Platform (ICTRP; http://who.int/ictrp/en/). We will
search all databases from their inception to the present, and we
will impose no restriction on language of publication.
Searching other resources
We will check reference lists of all primary studies and review
articles for additional references.
We will search for errata or retractions from included studies pub-
lished in full-text on PubMed (http://ncbi.nlm.nih.gov/pubmed)
and we will report the date of the search within the review.
Data collection and analysis
Selection of studies
Two review authors (KK and PM) will independently screen titles
and abstracts for inclusion of all the potential studies we identify
as a result of the search and will code them as either ’retrieve’ (el-
igible or potentially eligible/unclear) or ’do not retrieve’. We will
retrieve the full-text study reports/publications of studies in the
’retrieve’ category. Two review authors (KK and PM) will indepen-
dently screen the full-text articles and identify studies for inclu-
sion, and identify and record reasons for exclusion of the ineligible
studies. We will resolve any disagreement through discussion or,
if required, we will consult a third person. We will identify and
exclude duplicates and collate multiple reports of the same study
so that each study, rather than each report, is the unit of interest in
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the review. We will record the selection process in sufﬁcient detail
to complete a Preferred Reporting Items for Systematic Reviews
andMeta-Analyses (PRISMA) ﬂow diagram and a ’Characteristics
of excluded studies’ table (Moher 2009).
Data extraction and management
We will use a data collection form for study characteristics and
outcome data which we will pilot on at least one included study in
the review. Both review authors (KK and PM) will extract study
characteristics from the included studies. We will extract the fol-
lowing study characteristics.
1. Methods: study design, total duration of study, details of
any ’run in’ period, number of study centres and location, study
setting, withdrawals and the date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications and excluded medications.
4. Outcomes: primary and secondary outcomes speciﬁed and
collected and time points reported.
5. Notes: funding for trial and notable conﬂicts of interest of
trial authors.
Two review authors (KK and PM) will independently extract out-
come data from included studies. We will note in the ’Charac-
teristics of included studies’ table if a study reports outcome data
that are not usable in an analysis. We will resolve disagreements
by consensus or by involving a third person. One review author
(KK) will transfer data into the Review Manager (RevMan) ﬁle
(RevMan 2014). We will double-check that data is entered cor-
rectly by comparing the data presented in the systematic review
with the study reports.
Assessment of risk of bias in included studies
Two review authors (KK and PM) will independently assess the
risk of bias for each included study using the criteria outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). We will resolve any disagreements by discussion
or by involving a third person. We will assess the risk of bias of
each included study according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We will grade each potential source of bias as high, low or unclear
and provide a quote from the study report together with a justiﬁca-
tion for our judgment in the ’Risk of bias’ table.Wewill summarise
the ’Risk of bias’ judgements across different studies for each of
the domains listed. We will consider blinding separately for dif-
ferent key outcomes where necessary (e.g. for unblinded outcome
assessment, risk of bias for all-cause mortality may be very differ-
ent than for a patient-reported pain scale). Where information on
risk of bias relates to unpublished data or correspondence with a
trial author, we will note this in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations form it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as odds ratios and continuous
data as mean difference or standardised mean difference values.
We will enter data presented as a scale with a consistent direction
of effect.
We will undertake meta-analyses only where this is meaningful i.e.
if the treatments, participants and the underlying clinical question
are similar enough for pooling to make sense.
We will narratively describe skewed data reported as medians and
interquartile ranges.
Where multiple trial arms are reported in a single study, we will
include only the relevant arms. If we combine two comparisons
(e.g. two types of SDM versus usual care) in the same meta-anal-
ysis, we will halve the control group to avoid double-counting.
If both change from baseline and endpoint scores are available for
continuous data, we will use change from baseline unless most
studies report endpoint scores. If a study reports outcomes at mul-
tiple time points, we will use the end-of-study measurement.
When both an analysis that includes only participants who com-
pleted the trial and an analysis that imputed data for participants
who were randomly assigned but did not provide endpoint data
(e.g. last observation carried forward) are available, we will use the
latter.
Unit of analysis issues
For dichotomous outcomes, we will use participants, rather than
events, as the unit of analysis (i.e. number of people admitted to
hospital, rather than number of admissions per person). We will
onlymeta-analyse data from cluster RCTs if the available data have
been adjusted to account for the clustering.
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Dealing with missing data
We will contact investigators or study sponsors in order to verify
key study characteristics and obtain missing numerical outcome
data where possible (e.g. when we identify a study as an abstract
only). Where this is not possible, and we consider that the missing
data may introduce serious bias, we will explore the impact of
including such studies in the overall assessment of results by a
sensitivity analysis.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the
studies in each analysis. If we identify substantial heterogeneity we
will report it and explore possible causes by prespeciﬁed subgroup
analysis.
Assessment of reporting biases
If we are able to pool more than 10 studies, we will create and
examine a funnel plot to explore possible small study and publi-
cation biases.
Data synthesis
We will use a random-effects model and perform a sensitivity
analysis with a ﬁxed-effect model.
’Summary of findings’ table
We will create a ’Summary of ﬁndings’ table using the outcomes
listed in this protocol. We will use the ﬁve Grading of Recommen-
dations Assessment, Development and Evaluation (GRADE) con-
siderations (study limitations, consistency of effect, imprecision,
indirectness and publication bias) to assess the quality of a body
of evidence as it relates to the studies that contribute data to the
meta-analyses for the prespeciﬁed outcomes. We will use methods
and recommendations described in Section 8.5 and Chapter 12
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011), and will use GRADEproGuidelineDevelopment
Tool (GRADEpro GDT). We will justify all decisions to down-
grade or upgrade the quality of the evidence using footnotes and
we will make comments to aid the reader’s understanding of the
review where necessary.
Subgroup analysis and investigation of heterogeneity
We plan to perform the following subgroup analyses1 for the pri-
mary outcomes.
1. Age of the asthma population (children less than 12 years of
age, 12 to 18 years of age, adults over 18 years of age).
2. Focus of the intervention (i.e. population randomised to
the intervention: healthcare providers versus patient/parent).
3. Duration/extensiveness of intervention (e.g. one-off or
simple intervention versus ongoing SDM sessions).
1Children, adolescents and adults may have quite different needs
and preferences with respect to SDM, so interventions may have
different focuses and effects across age-groups. We also expect
study effects to vary regarding the focus and extent of the inter-
vention, which we will try to assess in the other two subgroup
analyses. However, since a subgroup analysis can only look at one
of these effect modiﬁers at a time and do not imply causation,
we will interpret the results cautiously. We will present these and
other possible effect modiﬁers in an additional table in the full
review.
We will use the formal test for subgroup interactions in RevMan
(RevMan 2014).
Sensitivity analysis
Weplan to carry out the following sensitivity analyses by removing
the following from the primary analyses.
1. Unpublished data.
2. Studies at high risk in either selection bias domain.
A C K N OW L E D G E M E N T S
The Background and Methods sections of this protocol are based
on a standard template used by the Cochrane Airways Group. We
are grateful for the advice and editorial expertise of the Cochrane
Airways Group staff, and in particular Rebecca Normansell for
advising us about aspects of this protocol.
Rebecca Normansell was the Editor for this protocol and com-
mented critically on the protocol draft.
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group’s Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
CENTRAL (The Cochrane Library) Monthly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
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Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Paciﬁc Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Condition search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufﬁciency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
17. exp Aspergillosis, Allergic Bronchopulmonary/
18. lung diseases, fungal/
19. aspergillosis/
20. 18 and 19
21. (bronchopulmonar$ adj3 aspergillosis).mp.
22. 17 or 20 or 21
23. 16 or 22
24. Lung Diseases, Obstructive/
25. exp Pulmonary Disease, Chronic Obstructive/
26. emphysema$.mp.
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27. (chronic$ adj3 bronchiti$).mp.
28. (obstruct$ adj3 (pulmonary or lung$ or airway$ or airﬂow$ or bronch$ or respirat$)).mp.
29. COPD.mp.
30. COAD.mp.
31. COBD.mp.
32. AECB.mp.
33. or/24-32
34. exp Bronchiectasis/
35. bronchiect$.mp.
36. bronchoect$.mp.
37. kartagener$.mp.
38. (ciliary adj3 dyskinesia).mp.
39. (bronchial$ adj3 dilat$).mp.
40. or/34-39
41. exp Sleep Apnea Syndromes/
42. (sleep$ adj3 (apnea$ or apnoea$)).mp.
43. (hypopnoea$ or hypopnoea$).mp.
44. OSA.mp.
45. SHS.mp.
46. OSAHS.mp.
47. or/41-46
48. Lung Diseases, Interstitial/
49. Pulmonary Fibrosis/
50. Sarcoidosis, Pulmonary/
51. (interstitial$ adj3 (lung$ or disease$ or pneumon$)).mp.
52. ((pulmonary$ or lung$ or alveoli$) adj3 (ﬁbros$ or ﬁbrot$)).mp.
53. ((pulmonary$ or lung$) adj3 (sarcoid$ or granulom$)).mp.
54. or/48-53
55. 23 or 33 or 40 or 47 or 54
Filter to identify randomised controlled trials (RCTs)
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT ﬁlter are adapted to identify trials in other electronic databases
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Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 shared* NEAR decision*:ti,ab
#6 sharing* NEAR decision*:ti,ab
#7 informed* NEAR decision*:ti,ab
#8 informed* NEAR choice*:ti,ab
#9 decision* NEAR aid*:ti,ab
#10 ((share* or sharing* or informed*) AND (decision* or deciding* or choice*)):ti
#11 MeSH DESCRIPTOR Decision Making
#12 MeSH DESCRIPTOR Decision Support Techniques
#13 MeSH DESCRIPTOR Decision Support Systems, Clinical
#14 MeSH DESCRIPTOR Choice Behavior
#15 decision* NEAR making*:ti,ab
#16 decision* NEAR support*:ti,ab
#17 choice* NEAR behavio?r*:ti,ab
#18 ((decision* or choice*) AND (making* or support* or behavior* or behaviour*)):ti
#19 MeSH DESCRIPTOR Patient Participation
#20 patient* NEAR participation*:ti,ab
#21 consumer* NEAR participation*:ti,ab
#22 patient* NEAR involvement*:ti,ab
#23 consumer* NEAR involvement*:ti,ab
#24 ((patient* or consumer*) AND (involvement* or involving* or participation* or participating*)):ti
#25 MeSH DESCRIPTOR Professional-Patient Relations
#26 MeSH DESCRIPTOR Physician-Patient Relations
#27 MeSH DESCRIPTOR Patient-Centered Care
#28 ((patient* or person* or client* or consumer*) NEAR (centred or centered or focussed or oriented)):ti,ab
#29 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23
or #24 or #25 or #26 or #27 or #28
#30 #4 AND #29
(Note: In search line #1, MISC1 denotes the ﬁeld in the record where the reference has been coded for condition, in this case, asthma).
C O N T R I B U T I O N S O F A U T H O R S
KK wrote the Background and Methods of this protocol with support from PM.
For the full review, KK and PM will both screen the search results, select studies for inclusion, extract data and assess the risk of bias
in the included studies. KK will conduct the analyses and write up the results, and both review authors will assess the quality of the
evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, interpret the ﬁndings
and prepare the manuscript for submission.
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